vTv Therapeutics (VTVT) Change in Receivables (2014 - 2024)
vTv Therapeutics' (VTVT) quarterly Change in Receivables came in at -$180000.0 in Q4 2024, down 276.47% year-on-year from $102000.0 in Q1 2024, and down 181.25% quarter-over-quarter from -$64000.0 in Q3 2024.
vTv Therapeutics (VTVT) Change in Receivables (2014 - 2024) Analysis & Trends
vTv Therapeutics has disclosed Change in Receivables across 10 years of filings, most recently posting -$180000.0 for Q4 2024.
- Change in Receivables for Q4 2024 came in at -$180000.0, down 276.47% year-over-year; the trailing twelve-month figure through Dec 2024 was -$40000.0 (up 43.66% YoY), and the FY2024 annual result was -$40000.0, up 43.66% from the prior year.
- Change in Receivables came in at -$180000.0 for Q4 2024 at vTv Therapeutics, down from -$64000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $928000.0 in Q3 2021 to a low of -$871000.0 in Q4 2021.
- The 5-year median for Change in Receivables is -$2000.0 (2021), against an average of $4133.3.
- Peak annual rise in Change in Receivables reached 6528.57% in 2021, while the deepest fall reached 704.86% in 2021.
- vTv Therapeutics' Change in Receivables stood at $144000.0 in 2020, then plunged by 704.86% to -$871000.0 in 2021, then soared by 113.32% to $116000.0 in 2022, then decreased by 12.07% to $102000.0 in 2023, then tumbled by 276.47% to -$180000.0 in 2024.
- The last three Change in Receivables figures came in at -$180000.0 (Q4 2024), -$64000.0 (Q3 2024), and -$675000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | vTv Therapeutics | 426.76 Mn | 426.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -180,000.00 |
| Dec 31, 2024 | -180,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -675,000.00 |
| Jun 30, 2024 | -675,000.00 |
| Mar 31, 2024 | 879,000.00 |
| Mar 31, 2024 | 879,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Mar 31, 2023 | -173,000.00 |
| Mar 31, 2023 | -173,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Sep 30, 2022 | -20,000.00 |
| Sep 30, 2022 | -20,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Dec 31, 2021 | -871,000.00 |
| Dec 31, 2021 | -871,000.00 |